Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

QR Code

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Enregistré dans:

Détails bibliographiques
Format:	article
Langue:	EN
Publié:	BMJ Publishing Group 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/32c795d1255f49a1b8eb8db0b8e04223
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
par: Min Yu, et autres
Publié: (2021)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
par: González-Cao M, et autres
Publié: (2015)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
par: Naoya Maekawa, et autres
Publié: (2021)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
par: Sjoerd H van der Burg, et autres
Publié: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
par: Yang Hu, et autres
Publié: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publié: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
par: Grecea M, et autres
Publié: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021)

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
par: Chao Liu, et autres
Publié: (2021)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publié: (2021)

Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
par: Naixue Yang, et autres
Publié: (2021)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
par: KE Ping, et autres
Publié: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
par: Shahram Salek-Ardakani, et autres
Publié: (2021)

The effect of hypoxia on PD-L1 expression in bladder cancer
par: Vicky Smith, et autres
Publié: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models
par: Woorim Kim, et autres
Publié: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
par: Hyun Tae Lee, et autres
Publié: (2017)

Regulatory Mechanism of PD-L1 Expression in Primary Liver Cancer
par: LI Shenghao, et autres
Publié: (2021)

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
par: Jia Chen, et autres
Publié: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
par: Jiang Q, et autres
Publié: (2021)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
par: Pascale Lejeune, et autres
Publié: (2021)

Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer
par: Yanyan Han, et autres
Publié: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
par: Shunichi Taki, et autres
Publié: (2021)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
par: Mariaelena Pierobon, et autres
Publié: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
par: Ye Peng, et autres
Publié: (2021)

Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
par: Anders Vikerfors, et autres
Publié: (2021)

Correction to: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma
par: Ao Zhang, et autres
Publié: (2021)

Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes
par: Johannes R. Graf, et autres
Publié: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
par: Jiamin Sheng, et autres
Publié: (2021)

Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
par: Hongji Zhang, et autres
Publié: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
par: Qing Li, et autres
Publié: (2021)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
par: Xin Zheng, et autres
Publié: (2021)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
par: Haihua He, et autres
Publié: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
par: Min Li, et autres
Publié: (2021)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
par: Kentaro Ohuchi, et autres
Publié: (2021)

How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
par: Xinran Wang, et autres
Publié: (2021)

MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas
par: Zheng Zhao, et autres
Publié: (2021)